Brief: Neuronetics Q2 Revenue USD 23 Million

Neuronetics

05/08/2025 12:05

Corrects revenue to $38.1 mln, from $23 mln, in Key Details table, and clarifies throughout to show revenue beats estimates

Overview

Neuronetics Q2 2025 revenue rises 132% yr/yr to $38.1 mln, beating estimates

U.S. clinic revenue from Greenbrook acquisition was $23.0 mln in Q2 2025

Company reduced cash used in operations to $3.5 mln, beating guidance

Outlook

Neuronetics expects Q3 revenue between $37 mln and $39 mln

Company maintains full-year revenue guidance of $149 mln to $155 mln

Neuronetics anticipates full-year gross margin between 48% and 50%

Company expects Q3 cash flow from operations to range from negative $3 mln to break-even

Result Drivers

GREENBROOK ACQUISITION - Revenue growth primarily driven by Greenbrook acquisition, contributing $23.0 mln in U.S. clinic revenue

NEUROSTAR DECLINE - NeuroStar Advanced Therapy System revenue decreased 13% due to strategic focus on higher volume accounts

TREATMENT SESSION PERFORMANCE - Record quarterly performance in treatment session revenue on pro forma basis, despite absence of Greenbrook sales

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beats
$38.1 mln
$36.80 mln (3 Analysts)
Q2 Gross Margin
46.6%
Q2 Operating Expenses
$25.80 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Neuronetics Inc is $7.00, about 33.4% above its August 4 closing price of $4.66

Press Release: ID:nGNX1SvD68

 (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)